Johnson & Johnson (NYSE:JNJ) received a $154.00 target price from research analysts at Credit Suisse Group in a research note issued on Monday. The firm currently has a “hold” rating on the stock. Credit Suisse Group’s price objective suggests a potential upside of 8.58% from the stock’s current price.
A number of other research firms have also recently commented on JNJ. Vetr raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $147.40 target price on the stock in a research note on Monday, January 1st. Royal Bank of Canada increased their target price on Johnson & Johnson from $144.00 to $147.00 and gave the company an “outperform” rating in a research note on Wednesday, October 18th. Citigroup started coverage on Johnson & Johnson in a research note on Monday, September 25th. They issued a “neutral” rating and a $140.00 target price on the stock. Jefferies Group raised Johnson & Johnson from a “hold” rating to a “buy” rating and increased their target price for the company from $145.00 to $157.00 in a research note on Wednesday, October 11th. Finally, Morgan Stanley reissued a “hold” rating and issued a $145.00 target price (up previously from $140.00) on shares of Johnson & Johnson in a research note on Wednesday, October 18th. Four investment analysts have rated the stock with a sell rating, eight have given a hold rating and ten have issued a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $145.94.
Johnson & Johnson (NYSE:JNJ) traded down $6.31 during trading on Monday, hitting $141.83. 17,470,000 shares of the stock traded hands, compared to its average volume of 6,160,000. The company has a market capitalization of $381,030.00, a PE ratio of 24.62, a P/E/G ratio of 2.76 and a beta of 0.80. Johnson & Johnson has a 52-week low of $110.76 and a 52-week high of $148.32. The company has a current ratio of 1.32, a quick ratio of 1.02 and a debt-to-equity ratio of 0.36.
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. BlackRock Inc. boosted its holdings in shares of Johnson & Johnson by 2.6% during the second quarter. BlackRock Inc. now owns 174,073,764 shares of the company’s stock worth $23,028,219,000 after purchasing an additional 4,332,612 shares during the period. Janus Henderson Group PLC boosted its holdings in shares of Johnson & Johnson by 717.9% during the second quarter. Janus Henderson Group PLC now owns 3,748,008 shares of the company’s stock worth $495,837,000 after purchasing an additional 3,289,763 shares during the period. Vanguard Group Inc. boosted its holdings in shares of Johnson & Johnson by 1.5% during the second quarter. Vanguard Group Inc. now owns 200,450,985 shares of the company’s stock worth $26,517,661,000 after purchasing an additional 3,023,110 shares during the period. Parametric Portfolio Associates LLC boosted its holdings in shares of Johnson & Johnson by 47.9% during the second quarter. Parametric Portfolio Associates LLC now owns 7,970,670 shares of the company’s stock worth $1,054,433,000 after purchasing an additional 2,581,562 shares during the period. Finally, Stifel Financial Corp boosted its holdings in shares of Johnson & Johnson by 6,715.9% during the third quarter. Stifel Financial Corp now owns 2,572,663 shares of the company’s stock worth $334,777,000 after purchasing an additional 2,534,918 shares during the period. Institutional investors and hedge funds own 65.72% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Credit Suisse Group Analysts Give Johnson & Johnson (JNJ) a $154.00 Price Target” was originally posted by American Banking and Market News and is the sole property of of American Banking and Market News. If you are viewing this news story on another website, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2018/01/23/credit-suisse-group-analysts-give-johnson-johnson-jnj-a-154-00-price-target.html.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
